German pharmaceutical company Bayer AG, Massachusetts General Hospital (MGH), and Brigham and Women's Hospital on Tuesday announced that they are collaborating to establish a lab in Boston that will focus on finding new treatments for chronic lung diseases.
Chronic lung disease encompasses a number of diseases of the airways and other structures of the lungs. One such disease, chronic obstructive pulmonary disease (COPD), affects about 65 million people and kills about three million people each year, making it the third-leading cause of death in the world.
Details on the lab
The lab, which will be located at Brigham and Women's Hospital in the Longwood Medical Area, will employ more than 20 scientists from Bayer, Brigham, and Massachusetts General Hospital.
To establish the lab, Bayer will invest more than $30 million to fund research projects over the next five years. Bayer, Brigham, and MGH will equally share rights to discoveries made through the venture.
The lab will also expand Bayer's presence in Boston, the company noted in a release. In 2018, the pharmaceutical company in a collaboration with the Broad Institute of MIT and Harvard University established a lab in Boston that focuses on cardiovascular diseases.
Paul Anderson, chief academic officer for Brigham and Women's, said the organizations behind the collaboration believe the model will "significantly accelerate the pace of discovery toward the goal of getting new therapies from the lab to patients safely and efficiently." He continued, "This collaboration provides the opportunity to integrate novel findings directly into the drug development pipeline, thus speeding up the time to move a new treatment into the clinic" (Bayer release, 9/24; Saltzman, Boston Globe, 9/24).